From: HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study
RAMs combinations after RAL use
Prevalence (%)
VIKING-3 [15]
This study
No INSTIs mutations
33
48
No Q148a
36
40
Q148 + 1 secondary mutationb
20
8
Q148 + ≥2 secondary mutationsb
11
4